Heviran Comfort Max (Aciclovir)

Heviran Comfort Max is prescribed for the management of infections caused by herpes simplex virus (HSV) and varicella‑zoster virus (VZV). It can be used both for acute episodes and for long‑term suppression in appropriate patients.

• Initial and recurrent genital herpes infections.
• Oral herpes (cold sores) caused by HSV‑1.
• Shingles (herpes zoster) in adults.
• Chickenpox (varicella) in immunocompetent individuals.
• Suppressive therapy to reduce recurrence of genital herpes.
• Post‑exposure prophylaxis for varicella in susceptible adults.
• Treatment of HSV‑related eye infections (herpes keratitis) under specialist supervision.

• Aciclovir, the active component of Heviran Comfort Max, is a nucleoside analogue that is selectively phosphorylated by viral thymidine kinase. The monophosphate is then converted by cellular kinases to aciclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporates into viral DNA, causing premature chain termination. Because activation depends on viral enzymes, the drug preferentially affects infected cells while sparing normal host tissue.

Adverse reactions to Heviran Comfort Max are generally mild, but serious events can occur rarely.

Common

• Nausea or vomiting.
• Diarrhea.
• Headache.
• Fatigue or weakness.
• Mild rash or itching.
• Dizziness or vertigo.
• Abdominal pain or discomfort.
• Loss of appetite.
• Taste disturbances (metallic taste).

Serious

• Acute kidney injury, especially in patients with pre‑existing renal impairment.
• Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hematologic abnormalities like neutropenia or thrombocytopenia (rare).
• Liver enzyme elevations indicating hepatic dysfunction.
• Confusion or hallucinations in renal‑compromised patients.
• Seizures in patients with high plasma concentrations.
• Anaphylactic reactions (rare).
• Cardiac arrhythmias in patients with electrolyte imbalance.

When prescribing Heviran Comfort Max, clinicians should consider several precautionary factors to ensure safe use.

• Assess renal function before initiation and adjust dose in patients with impaired clearance.
• Use caution in patients with a history of immune suppression or severe infections.
• Monitor for signs of hepatic dysfunction during prolonged therapy.
• Avoid use in patients with known hypersensitivity to aciclovir or related compounds.
• Consider pregnancy and lactation status; limited data are available, so risk‑benefit assessment is required.
• Evaluate for concomitant nephrotoxic medications that may increase aciclovir levels.

Heviran Comfort Max may interact with other medicines that affect renal elimination or share similar metabolic pathways.

Avoid

• Probenecid, because it reduces renal clearance of aciclovir and can increase toxicity.
• Cimetidine, which may raise plasma concentrations of aciclovir.
• High-dose intravenous aciclovir combined with nephrotoxic agents (e.g., aminoglycosides) due to additive kidney risk.
• Trimethoprim, which can compete for tubular secretion and raise aciclovir levels.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function.
• Loop diuretics, which can alter fluid balance and influence aciclovir excretion.
• Other antivirals (e.g., valacyclovir) – concurrent use may increase adverse effect potential.